Sugi Predict

Sugi Predict / Compounds / SCHEMBL355839

SCHEMBL355839

SCHEMBL355839

CS(=O)(=O)c1ccc(C=O)c(Cl)c1

nearest known ligand 0.53

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 1/20 0.53
▸ LMNA P02545 1/20 0.47
▸ PTGS2 P35354 4/20 0.41
▸ ERN1 O75460 2/20 0.41
▸ FAAH O00519 1/20 0.41
▸ MGLL Q99685 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ PDK1 Q15118 1/20 0.39
▸ PDK2 Q15119 1/20 0.39
▸ PDK3 Q15120 1/20 0.39
▸ PDK4 Q16654 1/20 0.39
▸ SCD O00767 1/20 0.39
▸ ENPP2 Q13822 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16795437 0.86 ERN1 (0.50) TDP1PTGS2ERN1
SCHEMBL21491267 0.85 LMNA (0.51) TDP1LMNAPTGS2ERN1ALDH1A1
SCHEMBL12593470 0.82 SMN1; SMN2 (0.52) LMNAPTGS2ERN1ALDH1A1ENPP2
SCHEMBL16031541 0.81 CA2 (0.58) TDP1LMNA
SCHEMBL9244819 0.81 TDP1 (0.53) TDP1LMNAERN1ALDH1A1MAPT
SCHEMBL20488975 0.80 VCAM1 (0.51) TDP1LMNAALDH1A1MAPT
SCHEMBL27313302 0.80 LMNA (0.47) LMNAPTGS2FAAHMGLLALDH1A1
SCHEMBL15814013 0.78 ALDH1A1 (0.43) TDP1LMNAPTGS2ERN1ALDH1A1
SCHEMBL755309 0.77 LMNA (0.60) LMNAPTGS2ALDH1A1MAPT
SCHEMBL16878248 0.77 PTGS2 (0.45) PTGS2ERN1SCDENPP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932264-B2 Sinomenine derivatives and preparation and uses thereof NATUREMED GROUP CORPORATION (US) 2011-04-26 — — US claimed
US-20250188070-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED 2025-06-12 — — US disclosed
CN-112236428-B Antiproliferative compounds and uses thereof 默克专利股份有限公司 2025-04-01 — — CN disclosed
US-12195453-B2 Antiproliferation compounds and uses thereof MERCK PATENT GMBH (DE) 2025-01-14 — — US disclosed
EP-4043460-B1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF MERCK PATENT GMBH (DE) 2024-06-05 — — EP disclosed
US-20230150993-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED 2023-05-18 — — US disclosed
US-20230150993-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED 2023-05-18 — — US disclosed
US-11440907-B1 Antiproliferation compounds and uses thereof MERCK PATENT GMBH (DE) 2022-09-13 — — US disclosed
EP-4043460-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF Merck Patent GmbH (DE) 2022-08-17 — — EP disclosed
EP-4043460-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF Merck Patent GmbH (DE) 2022-08-17 — — EP disclosed
EP-1963317-A1 USE OF PYRROLO [2 , 3-B]PYRIDINES TO PREPARE A MEDICAMENT FOR TREATING PAIN Novartis AG (CH) 2008-09-03 — — EP disclosed
US-20080114022-A1 (1-Benzyl-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-acetic acid; chemoattractant receptor-homologous molecule expressed on helper T-cells antagonist; antiinflammatory agent, antiallergen; obstructive airways disease NOVARTIS AG (CH) 2008-05-15 — — US disclosed
EP-1761529-B1 PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS NOVARTIS AG (CH) 2007-11-14 — — EP disclosed
CN-101035786-A Pyrrolopyridine derivatives and their use as CRTH2 antagonists NOVARTIS AG (CH) 2007-09-12 — — CN disclosed
WO-2007068418-A1 USE OF PYRROLO [2 , 3-B] PYRIDINES TO PREPARE A MEDICAMENT FOR TREATING PAIN NOVARTIS AG (CH) 2007-06-21 — — WO disclosed
EP-1761529-A2 PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS Novartis AG (CH) 2007-03-14 — — EP disclosed
US-20060079554-A1 Inhibitors of monomine uptake ELI LILLY AND COMPANY 2006-04-13 — — US disclosed
WO-2005123731-A2 PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS NOVARTIS AG (CH) 2005-12-29 — — WO disclosed
EP-1569905-A2 INHIBITORS OF MONOAMINE UPTAKE ELI LILLY AND COMPANY (US) 2005-09-07 — — EP disclosed
WO-2004052858-A2 INHIBITORS OF MONOAMINE UPTAKE ELI LILLY AND COMPANY (US) 2004-06-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114022-A1 (1-Benzyl-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-acetic acid; chemoattractant receptor-homologous molecule expressed on helper T-cells antagonist; antiinflammatory agent, antiallergen; obstructive airways disease CCR1, CCL2, CCL11 TDP1 4677/4885LMNA 3623/4885PTGS2 255/4885
US-20060079554-A1 Inhibitors of monomine uptake SLC6A2, SLC18A2, SLC6A3 TDP1 1175/4885LMNA 3580/4885PTGS2 2769/4885
US-12195453-B2 Antiproliferation compounds and uses thereof MKI67, MCL1, CCNI TDP1 1441/4885LMNA 1520/4885PTGS2 576/4885
US-11440907-B1 Antiproliferation compounds and uses thereof MKI67, MCL1, CCNI TDP1 1441/4885LMNA 1520/4885PTGS2 576/4885
US-20230150993-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF MKI67, MCL1, CCNI TDP1 1441/4885LMNA 1520/4885PTGS2 576/4885
US-20250188070-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF MKI67, MCL1, CCNI TDP1 1441/4885LMNA 1520/4885PTGS2 576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.